IL111991A - Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent - Google Patents

Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent

Info

Publication number
IL111991A
IL111991A IL11199194A IL11199194A IL111991A IL 111991 A IL111991 A IL 111991A IL 11199194 A IL11199194 A IL 11199194A IL 11199194 A IL11199194 A IL 11199194A IL 111991 A IL111991 A IL 111991A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
organic solvent
hiv protease
protease inhibitors
liquid pharmaceutical
Prior art date
Application number
IL11199194A
Other languages
English (en)
Other versions
IL111991A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL111991A0 publication Critical patent/IL111991A0/xx
Publication of IL111991A publication Critical patent/IL111991A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11199194A 1994-01-28 1994-12-15 Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent IL111991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18902194A 1994-01-28 1994-01-28
US28323994A 1994-07-29 1994-07-29

Publications (2)

Publication Number Publication Date
IL111991A0 IL111991A0 (en) 1995-03-15
IL111991A true IL111991A (en) 2000-07-26

Family

ID=26884695

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11199194A IL111991A (en) 1994-01-28 1994-12-15 Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent

Country Status (14)

Country Link
US (1) US5484801A (xx)
EP (1) EP0732923B1 (xx)
JP (1) JP4353542B2 (xx)
KR (1) KR100360963B1 (xx)
AT (1) ATE210441T1 (xx)
AU (1) AU700942B2 (xx)
CA (1) CA2178632C (xx)
DE (1) DE69524567T2 (xx)
DK (1) DK0732923T3 (xx)
ES (1) ES2169121T3 (xx)
HK (1) HK1011609A1 (xx)
IL (1) IL111991A (xx)
PT (1) PT732923E (xx)
WO (1) WO1995020384A1 (xx)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230402T1 (de) * 1992-12-29 2003-01-15 Abbott Lab Hemmer der retroviralen protease
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
EP0769936A1 (en) * 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
US5705524A (en) * 1994-11-04 1998-01-06 Gilead Sciences, Inc. Thiepane compounds
US6034118A (en) * 1994-11-04 2000-03-07 Gilead Sciences, Inc. Thiepane compounds
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
DK0861085T3 (da) 1995-11-13 2005-11-21 Vitaleech Bioscience N V Antivirale isolater opnået fra igler
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
AU3146997A (en) * 1996-06-03 1998-01-05 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
ES2169880T3 (es) 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6894171B1 (en) * 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CO5090830A1 (es) 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
WO2000028994A1 (en) * 1998-11-18 2000-05-25 Supratek Pharma Inc. Copolymer compositions for treating viral infections
MXPA01005884A (es) 1998-12-11 2002-04-24 Pharmasolutions Inc Composiciones auto-emulsionantes para medicamentos escasamente solubles en agua.
BE1012622A3 (fr) * 1999-04-21 2001-01-09 Solvay Procede pour la separation d'enantiomeres et reactif enantiopur.
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
KR100815412B1 (ko) † 1999-06-04 2008-03-20 아보트 러보러터리즈 개선된 약제학적 제형
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
EP1202626A4 (en) * 1999-07-20 2002-10-30 Merck & Co Inc ALPHA HYDROXY GAMMA (CARBOZYCLIC OR HETEROCYCLICALLY SUBSTITUTED) AMINOCARBONYLALKANAMIDE DERIVATIVES AND THEIR USE
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
AU777824B2 (en) 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
PT1248600E (pt) 2000-01-19 2008-08-25 Abbott Lab Formulações farmacêuticas melhoradas de inibidores da protease do vih
US7138538B2 (en) * 2000-04-14 2006-11-21 Solvay (Societe Anonyme) Process for the separation of enantiomers and enantiopure reagent
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
MXPA03001952A (es) * 2000-09-05 2003-09-10 Abbott Lab Sistemas saborizantes para composiciones farmaceuticas y metodos para hacer dichas composiciones.
KR100847679B1 (ko) * 2000-10-31 2008-07-23 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 피라논 프로테아제 억제제의 경구 투여 자가-유화 제형
WO2002051414A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Compositions médicinales s'administrant par voie orale
EP1374855A1 (en) * 2001-03-30 2004-01-02 Takeda Chemical Industries, Ltd. Medicinal solutions
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1575595A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim International GmbH Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
NZ545871A (en) * 2003-09-12 2010-04-30 Vertex Pharma Animal model for protease activity and liver damage
TW200528472A (en) 2003-10-10 2005-09-01 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7494660B2 (en) * 2003-10-27 2009-02-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1804821A4 (en) 2004-10-01 2009-07-15 Vertex Pharma INHIBITION OF HCV NS3-NS4A PROTEASE
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
WO2006090270A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Acid addition salt of 2-isopropyl-4-(((n-methyl)amino)methyl)thiazole and its?use in the preparation of ritonavir
BRPI0614620A2 (pt) * 2005-07-29 2011-04-12 Tibotec Pharm Ltd compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para preparar os referidos compostos, combinação e composição farmacêutica
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
MY144607A (en) * 2005-07-29 2011-10-14 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
ME01318B (me) * 2005-07-29 2013-12-20 Tibotec Pharm Ltd Makrociklički inhibitori virusa hepatitisa C
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
MY144895A (en) * 2005-07-29 2011-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
JP2009505966A (ja) 2005-08-02 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼのインヒビター
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392588A3 (en) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
CA2646229A1 (en) * 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
EP2097402B1 (en) 2006-11-17 2014-04-09 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
AU2008212758B2 (en) * 2007-02-08 2014-01-30 Medivir Ab Pyrimidine substituted macrocyclic HCV inhibitors
JP2010519330A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
ATE548044T1 (de) 2007-05-04 2012-03-15 Vertex Pharma Kombinationstherapie zur behandlung von hiv- infektionen
NZ583699A (en) * 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
AU2008305678A1 (en) * 2007-09-25 2009-04-02 Merck Sharp & Dohme Corp. HIV protease inhibitors
AP3010A (en) * 2007-10-29 2014-10-31 Cipla Ltd Novel antiretroviral combination
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
UY31950A (es) 2008-07-01 2010-01-29 Medivir Ab Inhibidores de ciclopropil-polimerasa
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
UA103801C2 (ru) 2009-04-25 2013-11-25 Ф. Хоффманн-Ля Рош Аг Способ повышения биодоступности ингибитора протеазы ns3/4a вируса гепатита с
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害薬
KR20120139699A (ko) 2010-01-29 2012-12-27 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 감염의 치료 요법
WO2012010942A2 (en) 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
EP3057976A1 (en) 2013-10-17 2016-08-24 Medivir Ab Hcv polymerase inhibitors
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086165A (en) * 1989-03-08 1992-02-04 Washington University Inhibitors of retroviral protease with a ketomethylene isosteric replaced amide bond
US5342922A (en) * 1989-03-08 1994-08-30 Washington University Inhibitors of retroviral protease
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5256677A (en) * 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5164300A (en) * 1989-12-28 1992-11-17 Washington University Method for determining activity of retroviral protease
JPH05508855A (ja) * 1990-07-06 1993-12-09 スミスクライン・ビーチャム・コーポレイション レトロウイルスプロテアーゼ阻害剤
US5171662A (en) * 1990-09-13 1992-12-15 The Upjohn Company Method of detecting HIV protease activity
US5183826A (en) * 1990-09-25 1993-02-02 Merck & Co., Inc. Antiviral agent
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
EP0575500A4 (en) * 1991-03-08 1994-06-01 Smithkline Beecham Corp Hiv protease inhibitors
EP0532466A3 (en) * 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
US5250563A (en) * 1991-09-25 1993-10-05 Merck & Co., Inc. Inhibitors of HIV protease
US5296604A (en) * 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
ATE230402T1 (de) * 1992-12-29 2003-01-15 Abbott Lab Hemmer der retroviralen protease

Also Published As

Publication number Publication date
AU700942B2 (en) 1999-01-14
WO1995020384A1 (en) 1995-08-03
ES2169121T3 (es) 2002-07-01
IL111991A0 (en) 1995-03-15
PT732923E (pt) 2002-05-31
US5484801A (en) 1996-01-16
EP0732923A1 (en) 1996-09-25
ATE210441T1 (de) 2001-12-15
DE69524567T2 (de) 2002-09-05
JP4353542B2 (ja) 2009-10-28
KR100360963B1 (ko) 2003-02-11
HK1011609A1 (en) 1999-07-16
AU1524895A (en) 1995-08-15
DK0732923T3 (da) 2002-04-08
CA2178632A1 (en) 1995-08-03
CA2178632C (en) 2006-04-11
EP0732923B1 (en) 2001-12-12
DE69524567D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
IL111991A (en) Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129300A0 (en) A liquid pharmaceutical composition comprising an HIV protease inhibitor or a combination of HIV protease inhibitors in a pharmaceutically acceptable organic solvent
CA2189351A1 (en) Narcotic containing aerosol formulation
GEP19991706B (en) (54) Heteroarylpiperidines, Pyrrolidines and Piperazines and Their Use As Antipsychotics and Analgetics
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
AU8047294A (en) Methods of treating menstrual symptoms and compositions therefore
ATE257389T1 (de) Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
ES2101449T3 (es) Inhibicion de la seborrea y el acne.
CA2259764A1 (en) Pharmaceutical compositions containing mupirocin
FI102475B1 (fi) Menetelmä farmaseuttisesti aktiivisten oktahydro- ja heksahydrobentso[f]kinolinonijohdannaisten valmistamiseksi
ES2161238T3 (es) Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para inhibir la angiogenesis y enfermedades angiogenicas.
NZ237309A (en) 1-(2-(4-morpholino)ethyl)-3-(arylcarbonyl)-indole derivatives and pharmaceutical compositions
AU3091802A (en) Oral dosage self-emulsifying formulations of pyranone protease inhibitors
CZ20011550A3 (cs) Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
UA37206C2 (uk) Фармацевтична композиція, яка містить алкілсульфонамід-агоніст 5нті- подібного рецептора для ректального введення
MX9602984A (es) Composiciones farmaceuticas que contienen inhibidores de proteasa de vih.
AU9221898A (en) Pharmaceutical coating composition and method of use
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
DK0771201T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
NO972435L (no) 2-(2,3,5,6-tetrafluor-4-pyridyl)-1,2,5-tradiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
AU6059094A (en) Active compound from a sponge
MX9702532A (es) Composiciones farmaceuticas para el tratamiento de la rinitis.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired